Next Generation Sequencing
Next Generation Sequencing is a genetic therapy with 31 clinical trials. Currently 8 active trials ongoing. Historical success rate of 88.9%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
72.7%
8 of 11 finished
27.3%
3 ended early
8
trials recruiting
31
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management
Next Generation Personalized Neuroblastoma Therapy
Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Solid Cancer
Solving Riddles Through Sequencing
RhEumatiC Heart diseAse Genetics
Clinical Trials (31)
Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management
Next Generation Personalized Neuroblastoma Therapy
Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Solid Cancer
Solving Riddles Through Sequencing
RhEumatiC Heart diseAse Genetics
Newer Therapeutic Targets in Head and Neck Cancers
NGS in Gallbladder Cancer and Response to Treatment
Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma
The Value of mNGS in Diagnosis of Pulmonary Infection
Evaluation of Next-Generation Sequencing-based Metabarcoding Versus Culturing for Microbiological Assessment in Infectious Keratitis
miRNA in Sweat, a Novel Digital Biomarker for Detection of Active Tuberculosis (TB)
Study to Assess the Feasibility in Bile cfDNA of Resectable Biliary Tract Carcinomas
Quest for Tumour Evolution of Non-small Cell Lung Cancer
DNA-mutation Analysis in Cyst Fluid of Suspected Intraductal Papillary Mucinous Neoplasia of the Pancreas
Urine-DNA Biomarkers in Detecting Bladder Cancer
Donor CHIP and Allogeneic HSCT Outcome
Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study
Development of Biomarker for the Evaluation of Response After Neoadjuvant Therapy in Patients With Pancreatic Cancer
Sterile Inflammation and Molecular Aberrations in MDS
Joint Microbiome Study for the Knee
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 31